Toceranib

In the field of veterinary medicine for pets, the emergence of targeted drugs has significantly improved the treatment outcomes of chronic inflammation and autoimmune diseases in dogs. Tocitinib is a Janus kinase (JAK) inhibitor specially designed for canines. By selectively inhibiting the JAK1 pathway, it blocks the signal transduction of pro-inflammatory cytokines, thereby rapidly alleviating inflammatory responses and reducing tissue damage. Clinically, it is mainly used to treat canine allergic dermatitis and atopic dermatitis, and can also be used as an adjuvant therapy for symptom control of immune-mediated diseases such as rheumatoid arthritis. It is one of the few precise targeted anti-inflammatory drugs in the current companion animal treatment field, providing affected dogs with a low-side-effect treatment option alternative to glucocorticoids.

The global pet anti-inflammatory drug market has continued to expand in recent years, among which the growth rate of the canine targeted anti-inflammatory drug segment has reached 12.3%. As a core variety in this field, the global market size of tocitinib exceeded USD 180 million in 2023. At present, the original research product occupies a dominant share in the overseas market, while the domestic market is still in the introduction stage, with only a small number of enterprises developing generic drugs. With the acceleration of the compliance process of domestic pet medication and the improvement of pet owners' requirements for the quality of life of pets, it is expected that the annual compound growth rate of domestic demand for tocitinib-related preparations and active pharmaceutical ingredients will exceed 25% in the next 3 years, with clear market growth space.

The original research enterprise of tocitinib is Zoetis, and the original trade name is Apoquel. The expiration date of its core compound patent in the United States is 2027, and the expiration date of the compound patent in China is 2026. The main dosage form of the original research product on the market is oral tablet, with three specifications of 3.6mg, 5.4mg and 16mg, which has been included in the FDA Reference Listed Drug Catalog for Animal Drugs. As of the search date, there is no approved generic tocitinib preparation marketed in China, and the CDE API Registration Platform has not yet announced any valid registration number of tocitinib API under review or approved. (Data as of October 2024, please refer to the official CDE website for the latest information.)

CATO provides a full set of tocitinib impurity reference standards. Most of the products are in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. They comply with the compliance requirements of multiple regulations including the Chinese Pharmacopoeia and FDA, and can fully meet the reference standard use needs of the whole process of API R&D, quality research and preparation declaration, providing stable and reliable supply chain support for the product R&D and commercialization promotion of relevant enterprises.